Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and...
71 insider purchases on record · latest filing 2026-06-24.
Insiders have also filed 14 sale transactions at IMRX.